Quick Answer
MiNK Therapeutics, Inc. reported Research And Development Expense of $5.76 million for the year ending 2025.
- MiNK Therapeutics, Inc. showed a decrease of -9.1% in Research And Development Expense from 2024 to 2025.
- This data is from MiNK Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $2.50 million | Q1 2021: $3.10 million | Q2 2021: $3.58 million | Q3 2021: $3.33 million | Q1 2022: $5.28 million | Q2 2022: $5.88 million | Q3 2022: $6.15 million | Q1 2023: $4.19 million | Q2 2023: $4.56 million | Q3 2023: $3.43 million | Q1 2024: $2.55 million | Q2 2024: $1.84 million | Q3 2024: $540.6 thousand | Q1 2025: $1.26 million | Q2 2025: $1.84 million | Q3 2025: $1.14 million.
- Over the full 6 years of available data (2020 to 2025), MiNK Therapeutics, Inc.'s Research And Development Expense has declined by 39.5%.
- Historical annual values: Fiscal year 2025: $5.76 million | Fiscal year 2024: $6.34 million | Fiscal year 2023: $15.49 million | Fiscal year 2022: $23.12 million | Fiscal year 2021: $13.97 million | Fiscal year 2020: $9.51 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: